Evidence map›Paper›PMID 38010271›Full record

ArticleCurrent protocols2023

Characterization of Klebsiella pneumoniae Extracellular Polysaccharides.

Saroj Khadka, Brooke E Ring, Drew A Pariseau, Laura A Mike

Open access · hybridAbstract read
In one paragraph

Article in Current protocols, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.

0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
1.3field-weighted citation impact, top 20% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

15 citing papers in PubMed, 14 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. TARGETING THE CAPSULE OFbioRxiv : the preprint server for biology · 2026
    Article
  6. Article
  7. Article
  8. Differential virulence potential of different clades of multidrug-resistantmedRxiv : the preprint server for health sciences · 2026
    Article
  9. Connections betweenInfection and immunity · 2026
    Article
  10. Targeting the capsule ofFrontiers in immunology · 2026
    Article
  11. Article
  12. Article
  13. Sugar Import SuppressesbioRxiv : the preprint server for biology · 2025
    Article
  14. Article
  15. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 2 institutions in 1 country.

Saroj KhadkaDepartment of Medical Microbiology and Immunology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Brooke E RingDepartment of Medical Microbiology and Immunology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Drew A PariseauDepartment of Medicine, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.
Laura A MikeDepartment of Medical Microbiology and Immunology, The University of Toledo College of Medicine and Life Sciences, Toledo, Ohio, USA.ORCID https://orcid.org/0000-0002-3368-4184
University of Toledo Medical Center · USUniversity of Toledo · US

Funding

UC San Diego RAPID Faculty Development Program in Infectious DiseasesR25AI147376 · NIAID · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI ADRIANA H TREMOULET, Joann Trejo · 2020 to 2026
$2.5M
Control of Klebsiella capsule biosynthesis and attachmentR35GM150588 · NIGMS · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI Laura Anzaldi Mike · 2023 to 2026
$1.6M
Functional Genetic Analysis of Klebsiella pneumoniae HypervirulenceK22AI145849 · NIAID · UNIVERSITY OF TOLEDO HEALTH SCI CAMPUS · PI MIKE, LAURA ANZALDI · 2021 to 2022
$269k
American Heart Association-American Stroke Association 23CDA1056712NIAID NIH HHS K22 AI145849NIAID NIH HHS R25 AI147376NIGMS NIH HHS R35 GM150588
6 · The paper itself

Abstract

Klebsiella pneumoniae is a clinically significant, Gram-negative pathogen in which the production of extracellular polysaccharides is a key virulence factor. Extracellular polysaccharides such as the capsule and its mucoviscosity play a significant role in K. pneumoniae infection. In this article, we explain several standard protocols used to characterize the extracellular polysaccharides of K. pneumoniae. Several of these protocols are adapted specifically for K. pneumoniae and describe methods to purify and quantify the extracellular polysaccharide of K. pneumoniae. We also present a standardized protocol to quantify K. pneumoniae mucoviscosity, a unique feature of K. pneumoniae extracellular polysaccharide. These protocols will help create uniformity in standard protocols used in K. pneumoniae extracellular polysaccharide studies. © 2023 The Authors. Current Protocols published by Wiley Periodicals LLC. Basic Protocol 1: Extracellular polysaccharide isolation and purification Basic Protocol 2: Large-scale isolation and purification of extracellular polysaccharide Basic Protocol 3: Uronic acid quantification of extracellular polysaccharide Basic Protocol 4: Extracellular polysaccharide visualization by SDS-PAGE Basic Protocol 5: Klebsiella pneumoniae mucoviscosity measurement by sedimentation resistance assay Alternate Protocol 5: 96-well plate-based Klebsiella pneumoniae sedimentation resistance assay Support Protocol 5: Determination of plate to cuvette conversion factor.

Indexed as

Klebsiella pneumoniaePolysaccharidesVirulence FactorsPolysaccharidesVirulence Factorscapsuleextracellular polysaccharidehypermucoviscosityKlebsiella pneumoniaesilver stain

Identifiers

PMID38010271
PMCPMC10683871
OpenAlexW4389069596

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.